X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NATCO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NATCO PHARMA FRESENIUS KABI ONCO./
NATCO PHARMA
 
P/E (TTM) x 22.1 16.7 132.3% View Chart
P/BV x 3.1 18.0 17.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   NATCO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO./
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs176877 20.1%   
Low Rs79424 18.5%   
Sales per share (Unadj.) Rs37.7223.4 16.9%  
Earnings per share (Unadj.) Rs5.131.1 16.4%  
Cash flow per share (Unadj.) Rs6.740.3 16.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5219.5 19.4%  
Shares outstanding (eoy) m158.2333.07 478.5%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.42.9 116.0%   
Avg P/E ratio x25.020.9 119.4%  
P/CF ratio (eoy) x18.916.1 117.2%  
Price / Book Value ratio x3.03.0 101.0%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m20,13521,504 93.6%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,128 62.4%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9637,389 80.7%  
Other income Rs m18167 10.8%   
Total revenues Rs m5,9817,556 79.2%   
Gross profit Rs m1,4301,793 79.7%  
Depreciation Rs m258304 84.7%   
Interest Rs m-26366 -7.1%   
Profit before tax Rs m1,2161,290 94.3%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342309 110.9%   
Profit after tax Rs m8061,027 78.4%  
Gross profit margin %24.024.3 98.8%  
Effective tax rate %28.123.9 117.6%   
Net profit margin %13.513.9 97.2%  
BALANCE SHEET DATA
Current assets Rs m5,1023,681 138.6%   
Current liabilities Rs m2,3853,123 76.4%   
Net working cap to sales %45.67.6 602.6%  
Current ratio x2.11.2 181.4%  
Inventory Days Days15089 167.7%  
Debtors Days Days11359 193.0%  
Net fixed assets Rs m5,1487,685 67.0%   
Share capital Rs m158331 47.8%   
"Free" reserves Rs m6,5566,670 98.3%   
Net worth Rs m6,7327,259 92.7%   
Long term debt Rs m952955 99.7%   
Total assets Rs m10,38811,957 86.9%  
Interest coverage x-45.84.5 -1,012.3%   
Debt to equity ratio x0.10.1 107.5%  
Sales to assets ratio x0.60.6 92.9%   
Return on assets %7.511.7 64.4%  
Return on equity %12.014.2 84.6%  
Return on capital %14.620.7 70.5%  
Exports to sales %74.539.4 189.2%   
Imports to sales %24.85.7 434.6%   
Exports (fob) Rs m4,4412,908 152.7%   
Imports (cif) Rs m1,477421 350.8%   
Fx inflow Rs m5,2983,445 153.8%   
Fx outflow Rs m1,772703 252.2%   
Net fx Rs m3,5252,743 128.5%   
CASH FLOW
From Operations Rs m1,2741,440 88.5%  
From Investments Rs m-1,204-1,089 110.6%  
From Financial Activity Rs m-196-353 55.6%  
Net Cashflow Rs m-126-1 8,476.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 1.5 5,510.2%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 9.6 16.6 57.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   42,599 25,395 167.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUN PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS